Clinical experience with Genotropin worldwide: an update March 1987.
The efficacy and safety of Genotropin (recombinant somatropin, KabiVitrum AB, Sweden) was analysed in 199 children with hGH deficiency, comprising a combined series of four current multicentre trials. Stimulation of linear growth from pretreatment height velocities of 3-4 cm/year to about 10 cm/year was observed after 6 and 9 months of treatment. Statistical analysis revealed significantly greater height velocities (by 2-3 cm/year) when the weekly dose of the hormone was given in 6-7 injections rather than in 3 injections. Immunogenicity seems to be very low, with only about 2% of the children having detectable antibodies during treatment.
Gunnarsson
R
R
Medical Department, KabiVitrum Peptide Hormones, Stockholm, Sweden.
Wilton
P
P
D001827:Body Height; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
D006728:Hormones; D011994:Recombinant Proteins; D013006:Growth Hormone